The DF/HCC Lymphoma and IVlyeloma Program includes a multidisciplinary group of 66 investigators from seven DF/HCC institutions who work together to explore the causes, define the pathogenetic mechanisms and improve the therapy of lymphoid neoplasms. At the time of the last CCSG renewal the Program received an Excellent to Outstanding merit score. Lymphoma and Myeloma Program members are: 1) experts in many of the most common lymphoid malignancies;2) investigators with lymphoma and myeloma research programs spanning basic, translational and clinical areas;3) dedicated clinical investigators;4) hematopathologists with demonstrated expertise in lymphoid malignancies;and 5) biostatisticians who specialize in these diseases. DF/HCC provides a mechanism for these lymphoma/myeloma investigators to have a cohesive program of basic and clinical investigation based upon complementary and synergistic areas of expertise. Program investigators received over $12.7 million peer-reviewed support in 2009, of which $7.5 million was from NCI funding. They also published 691 papers (33% intra-programmatic, 48% inter-programmatic and 37% inter-institutional) in the current funding period (2006 to 2010). The Lymphoma and Myeloma Program has the following specific objectives: 1) elucidate pathogenetic mechanisms underiying specific lymphoid neoplasms;2) develop novel therapeutic approaches to lymphoid malignancies;and 3) evaluate treatment outcomes and long-term complications in lymphoma and myeloma patients..
The Lymphoma and Myeloma Program is committed to characterizing specific lymphoid malignancies at both a cellular and molecular level using state-of-the-art approaches including informative in vivo models and comprehensive analysis of molecular signatures. In addition to gaining basic insights into pathogenetic mechanisms and predispo treatment targets.
|Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33|
|Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:|
|Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192|
|Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95|
|Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9|
|Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57|
|Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49|
|Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90|
|Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80|
|Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608|
Showing the most recent 10 out of 177 publications